


An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy

Primary Endpoints

- PFS
- OS



Trial Schema

Sponsor: University College London

Recruitment target: 618

Study Objectives

To assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance of olaparib alone in patients who have received combination platinum-based chemotherapy

Primary Endpoints

PFS (RECIST v1.1) and OS (death from any cause), measured from randomisation

Updates

- 35 UK sites, 58 international sites from 7 countries
- Contract signed with AZ in December 2016
- Submitted to REC and MHRA: October 2017
- Target open date: Q1 2018